Latest Conference Articles

When medication is not enough to treat epilepsy sometimes surgery can be a good choice for treatment. While the more common methods are also invasive in many ways there are newer procedures being developed that require less recovery time.

Diagnosing patients with epilepsy can often be an involved process as doctors will likely not see the seizures their patients report suffering. Once a diagnosis is made finding the right treatment can also be a challenge as different patient groups will require different types and doses of a variety of medications.

In the treatment of epilepsy there are constantly new drugs being developed to help patients manage their seizures. In the recent past there have been four new medications, each with their own benefits but also with their own risks as well.

For patients with Alzheimer's Disease, as their condition worsens it often falls on other members of their family to make decisions about their course of treatment. What they are expected to do and how they make certain decisions can have long lasting impacts on the care of the people with the disease.

One of the main focus points in the treatment of Alzheimer's Disease is screening patients before they even show symptoms of the condition. This is a part of the process that also includes looking to develop new treatments that could be used in the future.

While Alzheimer's Disease is not a new condition, finding a treatment has been elusive even as more is learned about it. Part of the diagnosis involves knowing what to look for beyond tests of cognition and other aspects of a patient's life.

Researchers are investigating whether microbial therapy can be an effective treatment for several skin and allergic conditions.

The gut microbiota modulates immune development and is an important component of neuroendocrine system. These interactions interfere with neuroendocrine development and, consequently, the patient's immune function.

Dietary amino acids are converted by the luminal microbiome in the gut to a bioactive compound, histamine, which binds to H2R and suppresses MAP kinase signaling and proinflammatory cytokines.

SLIT-tablets have a safety profile suitable for home treatment, as long as the first tablet intake is done under medical supervision. Long-term outcomes seem to differ between grass pollen SLIT-tablet products, and further studies are required.

Comparing safety and efficacy between sublingual immunotherapy and subcutaneous immunotherapy.

Multiple sclerosis, especially in the relapsing form poses a variety of challenges for patient care. Keeping that in mind, the development of medications for the condition also take time to progress.

Developing drugs for conditions like multiple sclerosis takes a long time and a considerable amount of research. How the drugs are used, and changed is a delicate process undertaken between doctors and their patients over the course of the disease.

Chronic conditions like multiple sclerosis require constant monitoring by doctors and patients, As time goes on medication and treatment options may need to be changed. Tecfidera, one popular treatment option has become a popular choice in patient care.

Researchers believe they have found a novel therapeutic to target a growth factor pathway that plays a role in liver cancer.

Another investigational diabetes drug appears to have promise for patients with nonalcoholic steatohepatitis, researchers reported at the International Liver Congress in Vienna, Austria.

The explosion in new drugs to treat hepatitis C is leading to predictions the viral infection will no longer be a major health problem. But before that can happen, much has to be done in the realm of public health, researchers said April 25 at the International Liver Congress in Vienna, Austria.

In addition to injection drug use, alcohol consumption puts people at risk of dying from hepatitis C infection by increasing the severity of the disease. A French research study spells out the risks.

The use of interferon to treat hepatitis C infections has fallen out of favor with the advent of new antivirals and drug combinations that have fewer side effects. But in a study presented at the 2015 International Liver Congress in Vienna, Austria, researchers from the UK said that physicians should put interferon back on the treatment menu.

The assumption used to be that after a liver transplant patients would need to take immunosuppressive drugs for years, even for life. A team of German researchers say that for about half of adult patients, that is no longer true.

In this video interview, Camille Barrault, MD, spoke about the implications her work with baclofen could have for the future of liver disease research at The International Liver Congress 2015, Vienna, Austria.

As good news about new treatments for hepatitis C infections continues to dominate the 2015 International Liver Congress, Texas researchers today reported more success with sofosbuvir and daclatasvir.

One cure for polycystic liver disease is a liver transplant-but since the disease is not fatal (the liver continues to do its job despite the problems the condition causes for patients), physicians face a treatment dilemma. A Belgian team offers an objective way to make the decision.

Video Interview: Vinood Patel, PhD, PGCHE, fHEA, FRSC, University of Westminster, London, UK, shared valuable insight regarding chronic alcoholic demographics and biomarkers on the horizon at The International Liver Congress 2015.

A new antiviral combination is showing promise in treating patients with both chronic kidney disease and chronic hepatitis C, Texas researchers reported at the International Liver Congress in Vienna, Austria.

Video Interview: Camille Barrault, MD discussed how her experiences with alcohol dependent patients correlated with her team's current research at The International Liver Congress 2015, Vienna, Austria.

When it comes to developing heart disease, patients who have non-alcoholic steatohepatitis (NASH) liver disease are at greater risk of both cardiovascular illness and death than patients with non-alcoholic fatty liver disease a UK team reported today at the International Liver Congress in Vienna, Austria.

Researchers in India have found a reliable and sensitive marker to predict how close to organ failure seriously ill patients with liver disease may be.

In the past year there has been a large amount of discussion about the best ways to treat stroke patients. While operations have become more accepted there are other less invasive steps that can be taken as well.

Active immunization for hepatitis B can be a cheaper, safe way to prevent infections that occur when liver transplant recipients are infected by donors' organs.